Hemangioma is the most common benign tumor in infants and children, with an incidence of about 10%, of which 2/3 occur in the head and neck. Most hemangiomas spontaneously resolve without any therapeutic intervention, with an ultimate regression rate of about 80%, but 20% of hemangiomas may affect body function, disfigure, or even threaten life, and therefore require aggressive intervention. There are many types of hemangiomas, with complex pathogenesis, and different treatment methods, including surgery, freezing, radiotherapy, local injection of sclerosing agent, laser and oral glucocorticoids, interferon, anti-cancer drugs, etc. The above methods are invasive and may leave scars, or have strong systemic toxic side effects, and the efficacy is often unsatisfactory, so they are hardly accepted by parents of children. In 2008, Leaute-Labreze et al. of the First Affiliated Hospital of the Chinese People’s Liberation Army General Hospital, Department of Dermatology, found that two infants with hemangiomas became lighter in color and reduced in extent when they were treated with propranolol for heart disease shortly after birth. They also administered the same treatment to 9 other children with maxillofacial hemangiomas and received the same results. The clinical use of Zindane, a non-selective adrenal beta-blocker, is mainly for the treatment of hypertension, supraventricular tachycardia, ischemic heart disease, and arrhythmias, and has been clinically proven to be safe and well tolerated for more than 40 years. This serendipitous discovery opened up a new era in the treatment of hemangioma, triggering scholars to pay attention to its clinical efficacy and mechanism of action, a large number of studies have shown that the rapid onset of action, obvious efficacy, and has a small side effect, non-invasive and other therapeutic advantages, is expected to become part of the first-line drugs for the treatment of hemangioma. So far, there have been a lot of reports about the application of the successful treatment of the face, eye, respiratory tract, liver and other with complications, multiple lesions, and even serious threat to the lives of children with serious hemangioma, and confirmed that the natural history of hemangioma can be changed, blocking its proliferation, in the proliferation and regression of hemangioma have significant effect. In addition, it can also be combined with dye laser and cryotherapy to achieve more desirable therapeutic effects. With the continuous research on the treatment of hemangioma, the author has reason to believe that the old drug “Jinan” will be expected as a first-line drug, become a new choice for the treatment of hemangioma.